Linnaeus Therapeutics, Inc., a Kairos portfolio company focused on the development and commercialization of novel small molecule oncology therapeutics, today...

Linnaeus Therapeutics announced the presentation of clinical data from its phase 1 dose-expansion study of LNS8801 as a monotherapy...

Linnaeus Therapeutics announced that the FDA has granted orphan drug designation for LNS8801 for the treatment of patients with...

Linnaeus Therapeutics, Inc. announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,369,618 ('618...

Linnaeus Therapeutics announced the presentation of clinical biomarker data from its study of LNS8801 as a monotherapy and in...

Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1/2 clinical trial of LNS8801 in combination...

Linnaeus Therapeutics, Inc. announced that the laboratory of Gary Schwartz, MD at Columbia University Irving Medical Center presented new findings...

Linnaeus Therapeutics announced it has been awarded a Phase 2 Bridge Small Business Innovation Research ("SBIR") Award by the...

Linnaeus Therapeutics announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts....

Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1 dose-escalation study of LNS8801 as a...